About Us

History

HomeAbout UsHistory

ABL Bio History

History of ABL Bio

ABL Bio

2019

  • 01. 01

    No. 1 Biotech in Korea

  • 01. 01

    Became the leader among biotech firms in developing therapeutic drugs for immuno-oncology and neurodegenerative diseases using bispecific antibody.

2018

  • 01. 01

    Series C Funding (paid-in capital of 70 billion KRW, June)

  • 01. 01

    Multiple contracts on bispecific antibody program and technology transfer

  • 01. 01

    IPO on KOSDAQ, Dec. 19, 2018 (90 billion KRW of public offering)

2017

  • 01. 01

    Series B Funding (paid-in capital of 20 billion KRW, March)

  • 01. 01

    ABL001 Clinical Trial Phase 1 (November)

2016

  • 01. 01

    ABL Bio Established (February)

  • 01. 01

    Series A Funding (paid-in capital of 9 billion KRW, March)